Working… Menu

Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04097704
Recruitment Status : Recruiting
First Posted : September 20, 2019
Last Update Posted : September 20, 2019
Information provided by (Responsible Party):

Brief Summary:

This is a multi-center observational follow-up study to collect saliva samples that allow pharmacogenetic analysis of the subjects that participated in the CC-90007-CP-003 study.

Approximately 28 subjects with moderate and severe hepatic impairment and healthy control subjects with normal hepatic function will be enrolled.

Condition or disease
Hepatic Insufficiency

Layout table for study information
Study Type : Observational
Estimated Enrollment : 28 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: An Observational Follow-on Study to Describe the Pharmacogenetics of the CC-90007-CP-003 Study Cohort
Actual Study Start Date : September 4, 2019
Estimated Primary Completion Date : October 15, 2019
Estimated Study Completion Date : October 15, 2019

Primary Outcome Measures :
  1. Percentage of subjects whose primary saliva sample yields DNA that meets modified PharmacoScan® workflow acceptability criteria [ Time Frame: Day 1 ]
    DNA Quality

Secondary Outcome Measures :
  1. Adverse Events (AEs) [ Time Frame: Time from ICF to Day 1 ]
    Number of participants with adverse event

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Approximately 28 subjects from the CC-90007-CP-003 study (from any race, males or non-pregnant and non-nursing females) will be enrolled. The study will be conducted at approximately 3 sites in the US that participated in the CC-90007-CP-003 study. Subjects may not be replaced with subjects that did not participate in the CC-90007-CP-003 study.

Inclusion Criteria:

Each subject must satisfy all of the following criteria to be enrolled in this study:

  1. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
  2. Subject is able to communicate with the Investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules and other protocol requirements.
  3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
  4. Subject participated in the CC-90007-CP-003 study.

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Subject has any condition which places the subject at unacceptable risk if he/she were to participate in the study.
  2. Subject has any condition that confounds the ability to interpret data from the study.

Sponsor's medical monitor should be consulted on suspected conditions under this exclusion criterion, prior to exclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04097704

Layout table for location contacts
Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599

Layout table for location information
United States, Florida
Clinical Pharmacology of Miami, LLC Not yet recruiting
Miami, Florida, United States, 33014-3616
Orlando Clinical Research Center OCRC Not yet recruiting
Orlando, Florida, United States, 32809
United States, Tennessee
Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville Recruiting
Knoxville, Tennessee, United States, 37920
Sponsors and Collaborators
Layout table for investigator information
Study Director: Leon Carayannopoulos, MD Celgene Corporation

Layout table for additonal information
Responsible Party: Celgene Identifier: NCT04097704     History of Changes
Other Study ID Numbers: NDS-CP-003
U1111-1237-0411 ( Other Identifier: WHO )
First Posted: September 20, 2019    Key Record Dates
Last Update Posted: September 20, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Information relating to our policy on data sharing and the process for requesting data can be found at the following link:

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: See Plan Description
Access Criteria: See Plan Description

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Celgene:
Hepatic impairment
Healthy Subject
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatic Insufficiency
Liver Failure
Liver Diseases
Digestive System Diseases